Patents by Inventor Peter Laing

Peter Laing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7807824
    Abstract: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: October 5, 2010
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
  • Publication number: 20100221808
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Application
    Filed: March 3, 2010
    Publication date: September 2, 2010
    Applicant: Lipoxen Technologies Limited
    Inventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
  • Patent number: 7691826
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: April 6, 2010
    Assignee: Lipoxen Technologies Limited
    Inventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
  • Publication number: 20100080844
    Abstract: A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.
    Type: Application
    Filed: September 24, 2009
    Publication date: April 1, 2010
    Inventors: Andrew David BACON, Peter Laing, Gregory Gregoriadis, Wilson Romero Caparros-Wanderley
  • Publication number: 20100056427
    Abstract: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatisation step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.
    Type: Application
    Filed: July 25, 2007
    Publication date: March 4, 2010
    Applicant: Lipoxen Technologies Limited London BioScience Innovation Centre
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Publication number: 20100022443
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 28, 2010
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20100016217
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 21, 2010
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 7604803
    Abstract: A composition for the co-delivery to a cell of a nucleic acid and an assistor protein, comprising vesicles, nucleic acid and protein, wherein the nucleic acid operatively encodes an antigenic protein or portion thereof which shares at least one epitope with the assistor protein, the composition comprising said nucleic acid and said assistor protein associated with the same vesicles as one another. A preferred embodiment is a composition comprising liposomes formed from liposome forming materials and, associated with the liposomes, nucleic acid operatively encoding an antigenic protein and an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein. The composition is for use as a vaccine and provides improved immune response compared to non-vesicular compositions, or mixtures of liposomes some of which are associated with nucleic acid and some of which are associated with assistor protein.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: October 20, 2009
    Assignee: Lipoxen Technologies Limited
    Inventors: Andrew David Bacon, Peter Laing, Gregory Gregoriados, Wilson Romero Caparros-Wanderley
  • Publication number: 20090117135
    Abstract: We describe a conjugate comprising an antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate.
    Type: Application
    Filed: January 7, 2009
    Publication date: May 7, 2009
    Inventors: Andrew Heath, Peter Laing
  • Publication number: 20090068254
    Abstract: A multivalent liposomal composition, preferably a vaccine, comprises liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigens of several serotypes and T-cell dependent protein carrier, such as tetanus toxoid. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Application
    Filed: September 29, 2006
    Publication date: March 12, 2009
    Applicant: Lipoxen Technologies Limited
    Inventors: Andrew David Bacon, Gregory Gregoriadis, Peter Laing
  • Publication number: 20080317838
    Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Application
    Filed: September 29, 2006
    Publication date: December 25, 2008
    Applicant: Lipoxen Technologies Limited
    Inventors: Andrew David Bacon, Gregory Gregoriadis, Peter Laing
  • Publication number: 20080132696
    Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd <1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.
    Type: Application
    Filed: August 12, 2005
    Publication date: June 5, 2008
    Inventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
  • Publication number: 20070191597
    Abstract: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
    Type: Application
    Filed: August 12, 2004
    Publication date: August 16, 2007
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Hreczuk-Hirst, Ioannis Papaioannou
  • Publication number: 20070053920
    Abstract: The invention relates to a set of novel immunological adjuvants based upon so called “polyladder” proteins of nematode worms. These proteins are typified by repeating units separated by a protease cleavage motif of RX(K/R)R or RXFR where R is ariginine, X is any amino acid, K is lysine and F is phenylalanine. These motifs are preceded by a cysteine residue at around 7, 8 or 9 residues upstream. Polyladder proteins or fragments of polyladder proteins may be used as immunological adjuvants either mixed with, or conjugated to a vaccine antigen, and will strongly enhance the immune response against the antigen. Conjugation may take the form of a genetic fusion between adjuvant and antigen. Antigens may be derived from pathogens, or may be tumour antigens, autoantigens, or antigens of other kinds. Vaccines may be used for prophylaxis or therapy.
    Type: Application
    Filed: January 21, 2004
    Publication date: March 8, 2007
    Inventors: Andrew Heath, Peter Laing
  • Publication number: 20060270830
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Application
    Filed: August 12, 2004
    Publication date: November 30, 2006
    Inventors: Dale Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Iaonnis Papaioannou
  • Patent number: 7083122
    Abstract: An atomizing injector includes a metering set having a swirl chamber, a spray orifice and one or more feed slots etched in a thin plate. The swirl chamber is etched in a first side of the plate and the spray orifice is etched through a second side to the center of the swirl chamber. Fuel feed slots extend non-radially to the swirl chamber. The injector also includes integral swirler structure. The swirler structure includes a cylindrical air swirler passage, also shaped by etching, through at least one other thin plate. The cylindrical air swirler passage is located in co-axial relation to the spray orifice of the plate of the fuel metering set such that fuel directed through the spray orifice passes through the air swirler passage and swirling air is imparted to the fuel such that the fuel has a swirling component of motion. At least one air feed slot is provided in fluid communication with the air swirler passage and extends in non-radial relation thereto.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: August 1, 2006
    Assignee: Parker-Hannifin Corporation
    Inventors: Adel B. Mansour, Rex J. Harvey, Peter Laing
  • Publication number: 20060165690
    Abstract: We describe a conjugate comprising an anti-CD40 or anti-CD28 antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate.
    Type: Application
    Filed: December 10, 2003
    Publication date: July 27, 2006
    Inventors: Andrew Heath, Peter Laing
  • Publication number: 20050220858
    Abstract: A composition for the co-delivery to a cell of a nucleic acid and an assistor protein, comprising vesicles, nucleic acid and protein, wherein the nucleic acid operatively encodes an antigenic protein or portion thereof which shares at least one epitope with the assistor protein, the composition comprising said nucleic acid and said assistor protein associated with the same vesicles as one another. A preferred embodiment is a composition comprising liposomes formed from liposome forming materials and, associated with the liposomes, nucleic acid operatively encoding an antigenic protein and an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein. The composition is for use as a vaccine and provides improved immune response compared to non-vesicular compositions, or mixtures of liposomes some of which are associated with nucleic acid and some of which are associated with assistor protein.
    Type: Application
    Filed: July 7, 2003
    Publication date: October 6, 2005
    Inventors: Andrew Bacon, Peter Laing, Gregory Gregoriadis, Wilson Caparros-Wanderley
  • Patent number: 6718770
    Abstract: A gas turbine engine fuel injector conduit includes a single feed strip having a single bonded together pair of lengthwise extending plates. Each of the plates has a single row of widthwise spaced apart and lengthwise extending parallel grooves. Opposing grooves in each of the plates are aligned forming internal fuel flow passages through the strip from an inlet end to an outlet end. The feed strip includes a substantially straight middle portion between the inlet end and the outlet end. In one alternative, the middle portion has a radius of curvature greater than a length of the middle portion. The feed strip has at least one acute bend between the inlet end and the middle portion and a bend between the outlet end and the middle portion. The feed strip has fuel inlet holes in the inlet end connected to the internal fuel flow passages.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: April 13, 2004
    Assignee: General Electric Company
    Inventors: Peter Laing, Michael Peter Wrubel, Barry Walford Savel, Rex Jay Harvey, Alfred Albert Mancini, James Neil Cooper, Robert Thane Mains
  • Patent number: 6711898
    Abstract: A fuel injector assembly for dispensing fuel in the combustion chamber of a gas turbine engine, includes in one embodiment an elongated, multi-layered, convoluted nozzle feed strip having an internal passage for directing fuel through the length of the strip from the inlet end to an outlet end; and a cylindrical, multi-layered fuel dispensing nozzle unitary with the feed strip and fluidly connected to the outlet end of the feed strip for dispensing the fuel. The multi-layered feed strip and nozzle allow complex porting of fuel circuits through the injector. The internal fluid passages through the feed strip and nozzle are formed by etching. In another embodiment, the feed strip can be used for directing fuel from the manifold to one or more fuel injectors.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: March 30, 2004
    Assignee: Parker-Hannifin Corporation
    Inventors: Peter Laing, Dale L. Arnold, Charles R. Bovard, Jeffrey R. Lehtinen